PCSK9 Inhibitors

Five things for pharma marketers to know: Wednesday, June 21, 2017

Five things for pharma marketers to know: Wednesday, June 21, 2017

By

Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections

Five things for pharma marketers to know: Friday, June 16, 2017

Five things for pharma marketers to know: Friday, June 16, 2017

By

Apple reportedly working to bring EMRs to iPhone; FDA to study disclosures in ads; Trump admin discussing drug price EO

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

By

Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.

Five things for pharma marketers to know: Friday, March 17, 2017

Five things for pharma marketers to know: Friday, March 17, 2017

By

The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug

Five things for pharma marketers to know: Monday, March 13, 2017

Five things for pharma marketers to know: Monday, March 13, 2017

By

Repatha reduces need for time-consuming procedure; Trump selects Gottlieb to lead the FDA; Acorda launches Alexa skill for MS

Five things for pharma marketers to know: Thursday, February 9, 2017

Five things for pharma marketers to know: Thursday, February 9, 2017

By

Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws

Five things for pharma marketers to know: Friday, February 3, 2017

Five things for pharma marketers to know: Friday, February 3, 2017

By

Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

By

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

Five things for pharma marketers to know: Friday, January 6, 2017

Five things for pharma marketers to know: Friday, January 6, 2017

By

Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending

Five things for pharma marketers to know: Wednesday, January 4, 2017

Five things for pharma marketers to know: Wednesday, January 4, 2017

By

Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology

Amgen's Repatha lowers plaque in arteries

Amgen's Repatha lowers plaque in arteries

By

New clinical data showed that Repatha, a PCSK9 inhibitor, reduced plaque in arteries when combined with a statin.

Five things for pharma marketers to know: Tuesday, November 1, 2016

Five things for pharma marketers to know: Tuesday, November 1, 2016

By

Facebook opens up to pharma; Pfizer nixes PCSK9 inhibitor in development; Cardinal Health cuts forecast on dwindling price increases

Drugmakers condemn ICER-funded study on PCSK9s

Drugmakers condemn ICER-funded study on PCSK9s

By

A new study published in JAMA said PCSK9 inhibitors are not worth their high prices.

Amgen wins PCSK9 patent case against Sanofi and Regeneron

Amgen wins PCSK9 patent case against Sanofi and Regeneron

By

A jury ruled in favor of Amgen, saying its patents for Repatha are valid.

Five things for pharma marketers to know: Tuesday, February 16, 2016

Five things for pharma marketers to know: Tuesday, February 16, 2016

By

Express Scripts revises PCSK9 inhibitor projections; research points to benefits of osteoporosis drugs; doctors consider emotional toll of cancer costs